Archive for the ‘malaria’ category

“Human Time Bomb for Mosquitoes”

July 12th, 2011

Echoing several articles published last week, Donald McNeil Jr. of the New York Times also shed light on the recent study conducted in the American Journal of Tropical Medicine and Hygiene by scientists from Senegal and Colorado State University.

As mentioned previously, the study demonstrated that ivermectin, a drug used to treat onchocerciasis, can also kill mosquitoes.

Scientists such as Dr. Peter Hotez, President of the Sabin Vaccine Institute, are enthusiastic about this study’s effects on combating malaria and other mosquito borne illnesses, however, the article also provided some cautious perspectives from others. For the drug to effectively kill mosquitoes, nearly everyone in an infested area would need to take the pill simultaneously. In addition, the mosquito killing effects fade after a month so ivermectin, which is typically only distributed once or twice a year to a community, would need to be distributed more frequently.

The article goes on to say, “Also, when people with lots of worms are treated, they suffer fever and intense itching as the worms die. Though that might be bearable once a year, it discourages people from seeking treatment more frequently. And ivermectin is dangerous for a few people — those infested with large numbers of a relatively rare West African worm, the loa loa. These worms circulate in the blood and lungs and may jam capillaries when they die, potentially causing coma or death. Detecting them means drawing blood and viewing it under a microscope.”

Read the full article here

Drug Used to Treat River Blindness Could Reduce Malaria Transmission

July 7th, 2011

A new study published in the American Journal of Tropical Medicine revealed that ivermectin, which is used to treat onchocerciasis (also known as river blindness) can also interrupt the transmission of malaria.

From an article on the study:

“The study by scientists from Senegal and Colorado State University found that transmission of malaria parasites by mosquitoes fell substantially among people living in several Senegalese villages over two weeks after they took the drug ivermectin, which was administered as part of a campaign to fight the parasitic roundworm that causes onchocerciasis, or river blindness. The drug appeared to kill malaria-carrying mosquitoes that fed on the blood of the villagers.”

Dr. Peter Hotez, President of the Sabin Vaccine Institute was also quoted in the article saying, “This study offers good news on several fronts, not the least of which is the potential to disrupt the transmission of malaria and save needless suffering and death. We need more creative science like this that has simple yet powerful results in our battle against neglected diseases of poverty. In terms of river blindness, this drug has transformed lives, said Hotez. “To add malaria to its already impressive return on investment would be an incredible development.”

Treating both NTDs and malaria simultaneously is cost-effective and will save many more lives in the long run. To find out how you can help the distribution of ivermectin and other drugs to treat NTDs for just 50 cents, please visit our Get Involved page.

Science magazine also had a write up on the study mentioning the work of the Global Network. The article quotes Dr. Hotez saying, “We’re only beginning to understand the enormous potential impact of MDAs on diseases for which they weren’t intended.”

WHO research programme on tropical diseases wins Gates Award

June 17th, 2011

The Special Programme for Research and Training in Tropical Diseases (TDR), based at WHO headquarters in Geneva and co-sponsored by UNICEF, UNDP, the World Bank and WHO, has won the 2011 Gates Award for Global Health.
TDR which has been operating since 1975, has supported and advocated for research and development to address infectious diseases and has had a major impact on reducing the burden of onchocerciasis, dengue, malaria, Chagas’ disease and visceral leishmaniasis .TDR will recieve $1 Million as a part of the reward which will go to expanding its fellowship and training programs.

Read the full press release here

New Editorial Highlights Importance of NTD Treatments Into Existing Control Programs for HIV-AIDs, TB and Malaria

June 2nd, 2011

Today, a new editorial authored by Peter Hotez, Jeffrey Sachs and others in the New England Journal of Medicine reinforces the importance of integrating neglected tropical disease (NTD) control measures into existing control efforts for HIV/AIDS, tuberculosis and malaria.

Highlighting a growing body of evidence from global health interventions over the past several years, the editorial argues that there are significant gains that can be achieved by adding treatments for the seven most prevalent NTDs to prevention and control programs targeting HIV/AIDS, tuberculosis and malaria, including those supported by the Global Fund to Fight AIDS, Tuberculosis and Malaria and the President’s Emergency Plan for AIDS Relief (PEPFAR).

At approximately 50 cents per per­son annually, the value of tying NTD control to other major health initiatives poses one of the most cost effective health interventions avail­able. The editorial also outlines the operational synergies of integrating control and elimination efforts into existing health interventions.  For instance, community drug distributors who provide ivermectin for onchocer­ciasis also provide insecticide-treated bed nets for malaria pro­tection, and bed nets appear to interrupt the transmission of lymphatic filariasis (and possibly other NTDs).

Additionally, low-cost anthelminthic drugs can be administered to pregnant women for intestinal helminth infections and schistosomiasis, thereby improving preg­nancy outcomes.  These drugs could be co-administered with intermittent preventive treatment (IPT) for malaria during pregnancy or with antiretroviral drugs for reducing mother-to-child HIV transmis­sion.

Click here to read the press release and here to access the NEJM website.